Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults

A vaccine would be an ideal tool for reducing malaria's impact. PfSPZ Vaccine (radiation attenuated, aseptic, purified, cryopreserved Plasmodium falciparum [Pf] sporozoites [SPZ]) has been well tolerated and safe in >1,526 malaria-naïve and experienced 6-month to 65-year-olds in the U.S., Europe, and Africa.

Sanaria and its Bioko Island Malaria Elimination Project partners win the Concordia P3 Impact Award and Audience Choice Award

The Bioko Island Malaria Elimination Project (BIMEP) is a long-term partnership dedicated since 2004 to the elimination of malaria from Equatorial Guinea which had one of the highest rates of malaria transmission and where the disease was the leading cause of morbidity and mortality.

Sanaria exhibits at annual Rockville Science Day

On April 22nd Sanaria participated at the 29th annual Rockville Science Day. Our exhibit featured different stages of the mosquito life cycle and a liquid nitrogen demonstration. For many of the children it was their first time looking through a microscope. At Sanaria we strive to engage with our community and foster scientific curiosity. Check out the future scientists:|

Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon

Abstract

Controlled human malaria infection (CHMI) by direct venous inoculation (DVI) with 3,200 cryopreserved Plasmodium falciparum sporozoites (PfSPZ) consistently leads to parasitemia and malaria symptoms in malaria-naive adults. We used CHMI by DVI to investigate infection rates, parasite kinetics, and malaria symptoms in lifelong malaria-exposed (semi-immune) Gabonese adults with and without sickle cell trait. Eleven semi-immune Gabonese with normal hemoglobin (IA), nine with sickle cell trait (IS), and five nonimmune European controls with normal hemoglobin (NI) received 3,200 PfSPZ by DVI and were followed 28 days for parasitemia by thick blood smear (TBS) and quantitative polymerase chain reaction (qPCR) and |

New film, Hope for Bioko, showcases Sanaria’s work

Fifteen years of malaria control on Bioko Island, initially by Medical Care Development International and later Sanaria Inc., represents one of the most progressive and successful Corporate Social Responsibility projects in the Global Health arena. The CSR partners in this program include Marathon Oil, Noble Energy, Equatorial Guinea Liquefied Natural Gas and Atlantic Methanol, and the important public sector financing and involvement has come from the Government of Equatorial Guinea.

Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial

Abstract

BACKGROUND:

Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive individuals. We aimed to assess the safety and protective efficacy of PfSPZ Vaccine against naturally acquired P falciparum in malaria-experienced adults in Mali.

METHODS:

After an open-label dose-escalation study in a pilot safety cohort, we did a double-blind, randomised, placebo-controlled trial based in Donéguébougou and surrounding villages in Mali. We recruited 18-35-year-old healthy adults who were randomly assigned (1:1) in a double-blind manner, with stratification by

|

The Quest for a Malaria Vaccine and the Man Who Risked Everything to Find It

Dr. Stephen Hoffman learned about malaria the hard way—by rolling up his sleeves and letting thousands of infected mosquitoes bite him.

Back in mid-1990s, Stephen Hoffman dipped his arm into a swarm of malaria-infected mosquitoes. But he didn’t expect to get sick. At the time, he thought he’d invented a vaccine that would keep him disease free.

He was wrong.

Read the full article in Mental Floss!|

Dr. David Dolberg, Sanaria’s Director of Intellectual Property, is recognized for his contributions to paradigm changing research in cancer

Sanaria Inc. is proud to recognize and celebrate the role of Dr. David Dolberg, Esq. ‐ Sanaria’s intellectual property attorney ‐ in helping to shape current approaches to the understanding and treatment of cancer. Prior to launching a career in law, David was a postdoctoral fellow in the laboratory of Dr. Mina Bissell at Berkeley, who was recently highlighted in a New York Times article by Gina Kolata, “Old Ideas Spur New Approaches in Cancer Fight” (December 29, 2009).

Contact Us


We welcome your feedback and inquiries. Please be in touch.

Address:

Sanaria Inc.
9800 Medical Center Drive, Suite A209
Rockville, MD 20850

Phone:

+1.301.770.3222

Social: